Evidence map›Paper›PMID 38697986›Full record

ArticleBlood cancer journal2024

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.

Mazyar Shadman, Alessandra Tedeschi, Leyla Mohseninejad, Keri Yang, Nicole Lamanna, Sheng Xu, Aileen Cohen, Swetha Challagulla, Mei Xue, Rhys Williams and 3 more

Abstract readLetterComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. BTK inhibitors: past, present, and future.Trends in pharmacological sciences · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mazyar ShadmanFred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA. mshadman@fredhutch.org.ORCID 0000-0002-3365-6562
Alessandra TedeschiASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Leyla MohseninejadBeiGene, Netherlands B.V., Schiphol, The Netherlands.
Keri YangBeiGene USA Inc, San Mateo, CA, USA.
Nicole LamannaHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Sheng XuBeiGene (Beijing) Co. Ltd., Beijing, China.
Aileen CohenBeiGene USA Inc, San Mateo, CA, USA.
Swetha ChallagullaBeiGene USA Inc, San Mateo, CA, USA.
Mei XueBeiGene USA Inc, San Mateo, CA, USA.
Rhys WilliamsBeiGene USA Inc, San Mateo, CA, USA.
Susan M O'BrienChao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA.
Jennifer R BrownDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2040-4961
Constantine TamThe Alfred Hospital and Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-9759-5017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenineLeukemia, Lymphocytic, Chronic, B-CellPiperidinesAgedFemaleHumansMaleMiddle AgedPyrazolesPyrimidinesTreatment OutcomeAdenineibrutinibPiperidinesPyrazolesPyrimidines

Identifiers

PMID38697986
PMCPMC11066086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.